CD274 and renal cell carcinoma: The introduction of checkpoint inhibitors resulted in durable responses and improvements in overall survival (OS) in advanced RCC patients [2,3,4,5], but the treatment efficacy is widely variable, and a considerable number of patients are resistant to PD-1/PD-L1 inhibition.